Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer's disease.

ABSTRACT:

Introduction

Blood-based biomarkers (BBMs) are promising tools for Alzheimer's disease (AD) diagnosis, but their accuracy may be affected by body mass index (BMI) and blood volume (BV) through dilution. We investigated how BMI and BV influence BBM concentrations and PET prediction.

Methods

Data from 241 cognitively unimpaired participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) were examined to evaluate the influence of BMI/BV on BBMs (Aβ_42/40, p-Tau₁₈₁, p-Tau₂₁₇, glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL]) and BBM-based PET predictions.

Results

Elevated BMI/BV associated with lower BBM concentrations, especially for p-Tau₂₁₇ and NfL, independent of brain amyloid burden. BMI-str

SUBMITTER: Jacobs T 

PROVIDER: S-EPMC12514939 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature